| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | E D Williamson | |
| G E Westlake | |||
| P2860 | cites work | Zika Virus | Q24261255 |
| A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA | Q24289279 | ||
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses | Q24617467 | ||
| Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis | Q24642708 | ||
| Drug-resistant TB: deadly, costly and in need of a vaccine | Q26765385 | ||
| Chikungunya: bending over the Americas and the rest of the world | Q26771903 | ||
| Zika: the origin and spread of a mosquito-borne virus | Q27469144 | ||
| The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting | Q27486846 | ||
| Plague Vaccine Development: Current Research and Future Trends | Q28066875 | ||
| The anthrax vaccine and research: reactions from postal workers and public health professionals | Q28384154 | ||
| A case for the ancient origin of coronaviruses | Q28681734 | ||
| Identification of a novel coronavirus in patients with severe acute respiratory syndrome | Q29615907 | ||
| A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
| Bats, civets and the emergence of SARS. | Q30364520 | ||
| The emergence of the Middle East respiratory syndrome coronavirus | Q33934034 | ||
| The pathogenesis of Rift Valley fever | Q34191969 | ||
| Variation in protection by BCG: implications of and for heterologous immunity | Q34288541 | ||
| Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
| Plague into the 21st century | Q34992582 | ||
| Russian vaccines against especially dangerous bacterial pathogens. | Q35050833 | ||
| Resistance of Yersinia pestis to antimicrobial agents | Q35091541 | ||
| The aetiology of SARS: Koch's postulates fulfilled | Q35214020 | ||
| Review of bats and SARS | Q35793577 | ||
| Mechanism study on a plague outbreak driven by the construction of a large reservoir in southwest china (surveillance from 2000-2015) | Q36296540 | ||
| Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. | Q36514844 | ||
| Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial | Q37264991 | ||
| Developing live vaccines against plague. | Q37599376 | ||
| Predictive models and correlates of protection for testing biodefence vaccines | Q37745002 | ||
| Yersinia pestis: examining wildlife plague surveillance in China and the USA. | Q37992283 | ||
| The natural history and incidence of Yersinia pestis and prospects for vaccination | Q37996390 | ||
| Development of vaccines against Crimean-Congo haemorrhagic fever virus | Q38688993 | ||
| ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice | Q40173497 | ||
| Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis | Q41476361 | ||
| Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. | Q41498914 | ||
| Current Status of Rift Valley Fever Vaccine Development | Q41929716 | ||
| Ecological Niche Modeling for Filoviruses: A Risk Map for Ebola and Marburg Virus Disease Outbreaks in Uganda. | Q42364377 | ||
| Outbreak of Zika Virus Infections, Dominica, 2016. | Q42650281 | ||
| A new virus isolated from the human respiratory tract | Q45825116 | ||
| Identification of Alpha and Beta Coronavirus in Wildlife Species in France: Bats, Rodents, Rabbits, and Hedgehogs. | Q46252081 | ||
| First vaccine approval under the FDA Animal Rule | Q47159419 | ||
| The Zika Virus Epidemic in Brazil: From Discovery to Future Implications | Q47556656 | ||
| Vaccine and Therapeutic Options To Control Chikungunya Virus | Q47566099 | ||
| Global economic evaluation of oral cholera vaccine: A systematic review | Q47628812 | ||
| Ecologic Features of Plague Outbreak Areas, Democratic Republic of the Congo, 2004-2014. | Q49219950 | ||
| Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases | Q49679334 | ||
| RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype | Q50029763 | ||
| New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. | Q53432317 | ||
| Melioidosis in Thailand: Present and Future. | Q55069370 | ||
| Airborne geographical dispersal of Q fever from livestock holdings to human communities: a systematic review and critical appraisal of evidence. | Q55176897 | ||
| CULTIVATION OF A NOVEL TYPE OF COMMON-COLD VIRUS IN ORGAN CULTURES. | Q55435801 | ||
| Yellow fever in Africa and the Americas: a historical and epidemiological perspective | Q56395584 | ||
| The 2017 plague outbreak in Madagascar: Data descriptions and epidemic modelling | Q56890695 | ||
| Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles | Q57182126 | ||
| Vaccines for preventing typhoid fever | Q57312007 | ||
| A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague | Q57459044 | ||
| Standardized guinea pig model for Q fever vaccine reactogenicity | Q57472233 | ||
| Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever | Q57476548 | ||
| Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy | Q59358897 | ||
| Tularemia transmission to humans: a multifaceted surveillance approach | Q64136251 | ||
| Dual route vaccination for plague with emergency use applications | Q90286584 | ||
| Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine | Q93357637 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 2 | |
| P921 | main subject | vaccine | Q134808 |
| vaccination | Q192995 | ||
| antibiotic resistance | Q380775 | ||
| emerging communicable disease | Q609748 | ||
| zoonosis | Q182672 | ||
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 170-183 | |
| P577 | publication date | 2019-04-11 | |
| 2019-11-01 | |||
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Vaccines for emerging pathogens: prospects for licensure | |
| P478 | volume | 198 |
| Q89622591 | Editorial: Molecular Vaccines Against Pathogens in the Post-genomic Era | cites work | P2860 |
Search more.